Alpha Profiles · Company Profile
ELI LILLY & Co
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world.
https://registry.alpha.ac/companies/eli-lilly-co
- Entity
- Public listing published
- Primary listing
- NYSE: LLY
- Verification
- Partially verified
- Last reviewed
- 2026-09-05T21:30:34.215281+00:00
Overview
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly
Canonical AEGIS identity graph
Executive leadership
Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.
Executive team
14 public recordsExecutive Vice President and President, Lilly Immunology
- State
- confirmed
- Effective
- Date not stated
- Confidence
- 94%
- Evidence
- LLY executive roster sourceMay 3, 2026
Executive Vice President, General Counsel and Secretary
- State
- confirmed
- Effective
- Date not stated
- Confidence
- 94%
- Evidence
- LLY executive roster sourceMay 3, 2026
- State
- confirmed
- Effective
- Date not stated
- Confidence
- 94%
- Evidence
- LLY executive roster sourceMay 3, 2026
Executive Vice President, Chief Scientific and Product Officer and President, Lilly Research Laboratories
- State
- confirmed
- Effective
- Date not stated
- Confidence
- 94%
- Evidence
- LLY executive roster sourceMay 3, 2026
Chair, President, and Chief Executive Officer (CEO)
- State
- confirmed
- Effective
- Date not stated
- Confidence
- 94%
- Evidence
- LLY executive roster sourceMay 3, 2026
- State
- confirmed
- Effective
- Date not stated
- Confidence
- 94%
- Evidence
- LLY executive roster sourceMay 3, 2026
Executive Vice President and President, Manufacturing Operations
- State
- confirmed
- Effective
- Date not stated
- Confidence
- 94%
- Evidence
- LLY executive roster sourceMay 3, 2026
Executive Vice President, Chief People Officer
- State
- confirmed
- Effective
- Date not stated
- Confidence
- 94%
- Evidence
- LLY executive roster sourceMay 3, 2026
Executive Vice President and President, Lilly USA and Global Customer Capabilities
- State
- confirmed
- Effective
- Date not stated
- Confidence
- 94%
- Evidence
- LLY executive roster sourceMay 3, 2026
Executive Vice President, President, Lilly Oncology and Head of Corporate Business Development
- State
- confirmed
- Effective
- Date not stated
- Confidence
- 94%
- Evidence
- LLY executive roster sourceMay 3, 2026
Executive Vice President and President, Lilly Cardiometabolic Health
- State
- confirmed
- Effective
- Date not stated
- Confidence
- 94%
- Evidence
- LLY executive roster sourceMay 3, 2026
Executive Vice President and Chief Financial Officer
- State
- confirmed
- Effective
- Date not stated
- Confidence
- 94%
- Evidence
- LLY executive roster sourceMay 3, 2026
Executive Vice President, Global Quality
- State
- confirmed
- Effective
- Date not stated
- Confidence
- 94%
- Evidence
- LLY executive roster sourceMay 3, 2026
Executive Vice President and President, Lilly International
- State
- confirmed
- Effective
- Date not stated
- Confidence
- 94%
- Evidence
- LLY executive roster sourceMay 3, 2026
Governance leadership
Boards & Committees
Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.
Record as of Sep 5, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.
Board roles
13 public records- State
- confirmed
- Effective
- From Jan 1, 2017
- Confidence
- 95%
- Evidence
- Eli Lilly director board sourceJan 1, 2017
- State
- unconfirmed
- Effective
- From Jan 1, 2025
- Confidence
- 85%
- Evidence
- ELI LILLY & Co DEF 14A 2026-03-20Mar 20, 2026
- State
- confirmed
- Effective
- From Mar 20, 2026
- Confidence
- 92%
- Evidence
- LLY DEF 14A director slateMar 20, 2026
- State
- confirmed
- Effective
- From Mar 20, 2026
- Confidence
- 92%
- Evidence
- LLY DEF 14A director slateMar 20, 2026
- State
- confirmed
- Effective
- From Mar 20, 2026
- Confidence
- 92%
- Evidence
- LLY DEF 14A director slateMar 20, 2026
- State
- unconfirmed
- Effective
- From Jan 1, 2024
- Confidence
- 85%
- Evidence
- ELI LILLY & Co DEF 14A 2026-03-20Mar 20, 2026
- State
- confirmed
- Effective
- From Mar 20, 2026
- Confidence
- 92%
- Evidence
- LLY DEF 14A director slateMar 20, 2026
- State
- confirmed
- Effective
- From Mar 20, 2026
- Confidence
- 92%
- Evidence
- LLY DEF 14A director slateMar 20, 2026
- State
- confirmed
- Effective
- From Mar 20, 2026
- Confidence
- 92%
- Evidence
- LLY DEF 14A director slateMar 20, 2026
- State
- confirmed
- Effective
- From Mar 20, 2026
- Confidence
- 92%
- Evidence
- LLY DEF 14A director slateMar 20, 2026
- State
- confirmed
- Effective
- From Mar 20, 2026
- Confidence
- 92%
- Evidence
- LLY DEF 14A director slateMar 20, 2026
- State
- confirmed
- Effective
- From Mar 20, 2026
- Confidence
- 92%
- Evidence
- LLY DEF 14A director slateMar 20, 2026
- State
- confirmed
- Effective
- From Jan 1, 2012
- Confidence
- 95%
- Evidence
- Eli Lilly director board sourceJan 1, 2012
Source record
Alpha canonical company public projection
Supports Company identity, Published leadership, Entity status boundary
Reviewed 2026-09-05T21:30:34.215281+00:00
ELI LILLY & Co Form 10-K (filed 2026-02-12)
Supports Official website
Reviewed 2026-08-29T22:18:05Z